Otsuka Holdings Co Ltd
TSE:4578

Watchlist Manager
Otsuka Holdings Co Ltd Logo
Otsuka Holdings Co Ltd
TSE:4578
Watchlist
Price: 8 910 JPY -0.47% Market Closed
Market Cap: 4.8T JPY
Have any thoughts about
Otsuka Holdings Co Ltd?
Write Note

Otsuka Holdings Co Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Otsuka Holdings Co Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Otsuka Holdings Co Ltd
TSE:4578
Pre-Tax Income
ÂĄ185.5B
CAGR 3-Years
-1%
CAGR 5-Years
3%
CAGR 10-Years
-2%
Takeda Pharmaceutical Co Ltd
TSE:4502
Pre-Tax Income
ÂĄ269.7B
CAGR 3-Years
-20%
CAGR 5-Years
N/A
CAGR 10-Years
6%
Daiichi Sankyo Co Ltd
TSE:4568
Pre-Tax Income
ÂĄ327.7B
CAGR 3-Years
52%
CAGR 5-Years
23%
CAGR 10-Years
10%
S
Shionogi & Co Ltd
TSE:4507
Pre-Tax Income
ÂĄ176.5B
CAGR 3-Years
12%
CAGR 5-Years
-10%
CAGR 10-Years
11%
Chugai Pharmaceutical Co Ltd
TSE:4519
Pre-Tax Income
ÂĄ540.2B
CAGR 3-Years
15%
CAGR 5-Years
24%
CAGR 10-Years
21%
Astellas Pharma Inc
TSE:4503
Pre-Tax Income
ÂĄ75.5B
CAGR 3-Years
-15%
CAGR 5-Years
-22%
CAGR 10-Years
-6%
No Stocks Found

Otsuka Holdings Co Ltd
Glance View

Market Cap
4.8T JPY
Industry
Pharmaceuticals

Otsuka Holdings Co., Ltd. is a Japanese pharmaceutical and nutraceutical powerhouse, woven into the fabric of global health and wellness. Founded in 1964, the company has consistently focused on the discovery, development, and commercialization of innovative products aimed at tackling unaddressed medical needs. Otsuka's broad portfolio includes prescription drugs, particularly in the areas of psychiatry, neurology, and oncology, complemented by a robust range of consumer healthcare products such as drinks and nutritional supplements. With a commitment to research and development, the company invests significantly in innovative drug solutions, resulting in a legacy marked by breakthroughs such as Abilify, a treatment for schizophrenia and bipolar disorder, and an array of lifestyle products that support overall well-being. For investors, Otsuka Holdings presents an intriguing blend of stability and growth potential. Its diversified business model mitigates dependence on any single market segment. The company’s strong financial foundation, supported by solid revenue from both its pharmaceutical and consumer health divisions, highlights its resilience even in challenging economic conditions. As Otsuka continues to expand its global footprint, particularly in emerging markets and through strategic partnerships, it positions itself to capitalize on the growing demand for innovative therapies and nutritional products. The company’s robust commitment to sustainability and social responsibility further enhances its attractiveness to investors looking for long-term value. With a vision centered on health, innovation, and quality of life, Otsuka stands as a formidable player in the healthcare landscape, poised for growth while delivering on its mission to create new products for a healthier world.

Intrinsic Value
9 473.82 JPY
Undervaluation 6%
Intrinsic Value
Price

See Also

What is Otsuka Holdings Co Ltd's Pre-Tax Income?
Pre-Tax Income
185.5B JPY

Based on the financial report for Sep 30, 2024, Otsuka Holdings Co Ltd's Pre-Tax Income amounts to 185.5B JPY.

What is Otsuka Holdings Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-2%

Over the last year, the Pre-Tax Income growth was -23%. The average annual Pre-Tax Income growth rates for Otsuka Holdings Co Ltd have been -1% over the past three years , 3% over the past five years , and -2% over the past ten years .

Back to Top